Fingerprint
Dive into the research topics where Kari L. Kendra is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial
Kendra, K. L., Bellasea, S. L., Eroglu, Z., Hu-Lieskovan, S., Campbell, K. M., Carson, W. E., Wada, D. A., Plaza, J. A., In, G. K., Ikeguchi, A., Hyngstrom, J., Brohl, A. S., Chmielowski, B., Khushalani, N. I., Markowitz, J., Monroe, M., Contreras, C. M., Bowles, T., Norman, K. & Medina, E. & 13 others, , Feb 2026, In: Nature Cancer. 7, 2, p. 272-282 11 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Link opens in a new tab Scopus citations -
A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade
Angell, C. D., Sun, S. H., Lapurga, G., Benner, B., Quiroga, D., Savardekar, H., Divincenzo, M. J., Abood, D., Stiff, A., Duggan, M., Handley, D., Nagle, E., Howard, J. H., Shah, H., Kendra, K. L. & Carson, W. E., Apr 1 2025, In: Melanoma research. 35, 2, p. 102-108 7 p.Research output: Contribution to journal › Article › peer-review
-
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial
Kendra, K. L., Bellasea, S. L., Eroglu, Z., Hu-Lieskovan, S., Campbell, K. M., Carson, W. E., Wada, D. A., Plaza, J. A., Sosman, J. A., In, G. K., Ikeguchi, A., Hyngstrom, J., Brohl, A. S., Khushalani, N. I., Markowitz, J., Negrea, G., Kasbari, S., Doolittle, G. C., Swami, U. & Roberts, T. & 13 others, , Nov 2025, In: Nature Medicine. 31, 11, p. 3668-3674 7 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Scopus citations -
BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy
Savardekar, H., Stiff, A., Liu, A., Wesolowski, R., Schwarz, E., Garbarine, I. C., Duggan, M. C., Zelinskas, S., Li, J., Lapurga, G., Abreo, A., Savardekar, L., Parker, R., Sabella, J., DiVincenzo, M. J., Benner, B., Sun, S. H., Quiroga, D., Scarberry, L. & Xin, G. & 8 others, , Dec 15 2025, In: Journal of Clinical Investigation. 135, 24, p. 1-15 15 p., e181975.Research output: Contribution to journal › Article › peer-review
Open Access -
BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy
Savardekar, H., Stiff, A., Liu, A., Wesolowski, R., Schwarz, E., Garbarine, I. C., Duggan, M. C., Zelinskas, S., Li, J., Lapurga, G., Abreo, A., Savardekar, L., Parker, R., Sabella, J., DiVincenzo, M. J., Benner, B., Sun, S. H., Quiroga, D., Scarberry, L. & Xin, G. & 8 others, , Oct 1 2025, In: The Journal of clinical investigation. 135, 19Research output: Contribution to journal › Article › peer-review
Open Access3 Link opens in a new tab Scopus citations